Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-990-5740
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$46.97 million
Profitability
Miscellaneous
Employees124
Next Earnings Date7/29/2019 (Estimated)
OptionableOptionable
Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences Inc (NASDAQ:ALIM) issued its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The biopharmaceutical company earned $11.14 million during the quarter, compared to the consensus estimate of $11.12 million. View Alimera Sciences' Earnings History.
When is Alimera Sciences' next earnings date?
What price target have analysts set for ALIM?
3 brokerages have issued twelve-month price targets for Alimera Sciences' stock. Their predictions range from $2.75 to $3.00. On average, they expect Alimera Sciences' share price to reach $2.9167 in the next year. This suggests a possible upside of 220.5% from the stock's current price. View Analyst Price Targets for Alimera Sciences.
What is the consensus analysts' recommendation for Alimera Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.
What are Wall Street analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (5/2/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $202M. This includes a discounted cash flow based enterprise value of the firm at $272M, excluding $40M debt and $30M preferred stock. The DCF analysis utilizes a 15% discount rate and a 2% terminal growth rate. Risks include, but are not limited to: (1) failure of ILUVIEN to secure additional regulatory approval; (2) failure of ILUVIEN to achieve commercial success due to market size, penetration rate, and/ or competition; and (3) potential dilution risk." (5/2/2019)
Has Alimera Sciences been receiving favorable news coverage?
Media coverage about ALIM stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alimera Sciences earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Protagonist Therapeutics (PTGX), Concert Pharmaceuticals (CNCE), Aduro BioTech (ADRO), Xenon Pharmaceuticals (XENE), Evelo Biosciences (EVLO), Aratana Therapeutics (PETX), MannKind (MNKD), MEI Pharma (MEIP), Marinus Pharmaceuticals (MRNS), Lannett (LCI), Aclaris Therapeutics (ACRS), Minerva Neurosciences (NERV), Kamada (KMDA), Cerecor (CERC) and AcelRx Pharmaceuticals (ACRX).
What other stocks do shareholders of Alimera Sciences own?
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
- Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
- Dr. Kenneth Green, Consultant (Age 61)
- Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
- Mr. J. Philip Jones, Chief Financial Officer (Age 55)
Who are Alimera Sciences' major shareholders?
Alimera Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.41%), Royce & Associates LP (0.80%), Knott David M (0.57%), B. Riley Financial Inc. (0.40%), B. Riley Wealth Management Inc. (0.20%) and Columbia Pacific Advisors LLC (0.07%). Company insiders that own Alimera Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.
Which major investors are selling Alimera Sciences stock?
Which major investors are buying Alimera Sciences stock?
ALIM stock was bought by a variety of institutional investors in the last quarter, including Royce & Associates LP, Renaissance Technologies LLC, Columbia Pacific Advisors LLC, Charles Schwab Investment Management Inc., B. Riley Wealth Management Inc. and Knott David M. Company insiders that have bought Alimera Sciences stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.
How do I buy shares of Alimera Sciences?
Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of ALIM stock can currently be purchased for approximately $0.9099.
How big of a company is Alimera Sciences?
Alimera Sciences has a market capitalization of $64.60 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.
What is Alimera Sciences' official website?
How can I contact Alimera Sciences?
Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]
MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
